Slide 1: Transforming Discovery of Therapeutics and Materials
Transforming Discovery of Therapeutics and Materials August 2, 2023
Slide 2: Cautionary Note and Disclaimer
Cautionary Note and Disclaimer This presentation contains certain "forward-looking statements" within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 that involve substantial risks and uncertainties. All statements, other than statements of historical fact, contained in this
Slide 3: Schrödinger's Balanced Business Model
Schrödinger’s Balanced Business Model SOFTWARE LICENSING COLLABORATIONS • Life Sciences • Materials Design PROPRIETARY PIPELINE • Drug Design ~1,750 customers worldwide* • Materials Design • Drug Discovery & Development • Wholly-owned or Partnered 13 active projects • 19 active programs TECHNOLOGY P
Slide 4: Highlights
Highlights • Continued dosing in patients with advanced B cell malignancies SGR-1505 • International expansion underway • Ongoing dose escalation in Phase 1 study in healthy volunteers • IND cleared; Phase 1 trial in acute myeloid leukemia and myelodysplastic syndrome SGR-2921 expected to initiate t
Slide 5: Long-Term Quarterly Revenue Trend
Long-Term Quarterly Revenue Trend 2Q23 Revenue 70 Software 64.8* Discovery • Total revenue -8.5% YoY 60 56.8 48.7 9.0 • Software revenue -2% YoY 50 46.2 32.6 due to lower contribution 7.6 15.6 38.5 37.0 from selected service $ (Millions) 40 35.2 29.8 29.8 8.5 contracts 12.3 5.8 30 5.7 5.6 47.8 • Dru
Slide 6: Four-Quarter Trailing Average Quarterly Revenue Trend
Four-Quarter Trailing Average Quarterly Revenue Trend Total Revenue, trailing four-quarter average 50 49.3 48.4 Software 45.2 Discovery 42.6 40.8 15.6 14.9 40 38.6 11.3 11.0 34.5 9.3 8.6 31.2 30.2 6.2 30 28.5 27.0 6.3 25.2 5.6 $ (Millions) 4.7 23.8 3.9 22.8 3.9 4.2 20 4.8 33.9 33.7 33.5 30.0 31.5 31
Slide 7: 2Q23 Financial Highlights vs. 2Q22
2Q23 Financial Highlights vs. 2Q22 Three Months Ended June 30 2022 2023 % Change (in millions) Total revenue $38.5 $35.2 (8.5%) Software revenue $30.0 $29.4 (2.2%) Drug discovery revenue $8.5 $5.8 (31%) Gross profit $17.1 $13.8 (19%) Software gross margin 76% 77% Operating expenses $60.6 $74.9 24% O
Slide 8: 2023 Financial Guidance
2023 Financial Guidance (as of August 2, 2023) Year-to-Date Previous FY23 Revised FY23 Expectation FY22 Actual 2Q23 Guidance* Guidance* Total revenue $181.0 $100.0M – – Software revenue $135.6M $61.6M 13% - 17% 15% - 18% Drug discovery revenue $45.4M $38.4M $70-90M $50-70M Operating expense 40% 29%
Slide 9: Platform Validated by Advancing Collaboration Programs
Platform Validated by Advancing Collaboration Programs(1)(2) FDA FDA PROGRAM Discovery Preclinical Phase 1 Phase 2 Phase 3 Approved PROGRAM Discovery Preclinical Phase 1 Phase 2 Phase 3 Approved TIBSOVO* CNS IDHIFA* Autoimmune Disease Oncology Oncology Oncology Pulmonary Arterial Hypertension Antifu
Slide 10: Retained and Partnered Proprietary Programs
Retained and Partnered Proprietary Programs PROGRAM DISCOVERY PRECLINICAL PHASE I PROGRAM DISCOVERY PRECLINICAL CLINICAL RIGHTS SGR-1505 (MALT1) SOS1 Relapsed / Resistant RAS-Mutant Cancers Non-Hodgkin’s Lymphoma Undisclosed Oncology SGR-2921 (CDC7) Undisclosed Hematological Cancers Oncology and Sol
Slide 11: Advancing Programs with Breakthrough Potential
Advancing Programs with Breakthrough Potential Status and anticipated next steps SGR-1505 (MALT1) SGR-2921 (CDC7) SGR-3515 (Wee1) IND-enabling studies • Clinically validated target for • Key cell cycle checkpoint for • Therapeutic potential underway foracross a leukemias and lymphomas DNA repair bro
Slide 12: Upcoming Milestones
Upcoming Milestones • Add U.S. and international study sites for SGR-1505 (MALT1) Phase 1 trial • Report initial SGR-1505 healthy volunteer data • Initiate Phase 1 trial of SGR-2921 (CDC7) in acute myeloid leukemia and myelodysplastic syndrome • Advance IND-enabling studies for SGR-3515 (Wee1) • Pip
Slide 13: Summary
Summary Encouraging outlook for Emerging portfolio of Continued commitment to Solid 2Q23 Performance expanded software proprietary medicines collaborations deployments SOFTWARE LICENSING COLLABORATIONS PROPRIETARY PIPELINE Steady revenue growth Inflecting revenue growth TECHNOLOGY PLATFORM 13
Slide 14: Transforming Discovery of Therapeutics and Materials
Transforming Discovery of Therapeutics and Materials August 2, 2023